PHASE II CLINICAL STUDY OF PEGYLATED LIPOSOMAL DOXORUBICIN HYDROCHLORIDE INJECTION AS 2ND-LINE OR LATER THERAPY IN PATIENTS WITH MULLERIAN CARCINOMA (EPITHELIAL OVARIAN CARCINOMA, PRIMARY CARCINOMA OF FALLOPIAN TUBE, PERITONEAL CARCINOMA) HAVING PRIOR PLATINUM-BASED CHEMOTHERAPY: